Stadler et al., study showed that LCAT activity was not associated with the incidence of atherosclerotic cardiovascular events or kidney function decline during a 5-year follow-up in 453 non-dialysis CKD patients from the CARE FOR HOMe study. This evidence concerns the gene LCAT and chronic kidney disease.